New tool to drive multiple myeloma research

US myeloma patient leads new platform, Healthtree, which has been created to cater to the unmet needs of the multiple myeloma community


The Myeloma Crowd, a division of US-based cancer research firm CrowdCare Foundation, has announced the launch of its new online tool, HealthTree, which will aim to provide a patient-centric solution for multiple myeloma treatments.

HealthTree, powered by Myeloma Crowd, utilizes a patient-powered research database led by former IBM systems engineer and myeloma patient Jenny Ahlstrom and her husband Paul.

"The healthcare industry still acts as if the internet doesn't exist with every patient having to reinvent the wheel to learn about their disease," Ahlstrom said.

"HealthTree gives the 80% of patients not seeing a myeloma specialist access to information from the experts that they can share with their doctor. Patients could be living years longer with today's wide range of therapies if they received the right treatment at the right time," she added

Visit Innovation Enterprise's AI & Big Data for Pharma Summit in New York, part of DATAx New York, on December 12–13, 2018

According to Myeloma Crowd, HealthTree is the first of its kind to offer patients the ability to discover relevant treatments and clinical trials, view collective reports of anonymized data and provide de-identified data to be aggregated for review by myeloma researchers and the patient community.

Additionally, Myeloma Crowd said that the Ahlstroms had completed a 50-city tour in the US for HealthTree during the beta test. The tool is free to use for myeloma patients, Myeloma Crowd stated that "to date, there are already almost a thousand patients are now using the tool that will enable new hypotheses around a cure by sharing their myeloma data and experiences".

"Once the needs in myeloma are fully met, there are plans to expand HealthTree to other types of cancer and terminal diseases in the future," Myeloma Crowd added.

How to take the risk out of saas development small

Read next:

How to take the risk out of SaaS development